Results 1 to 10 of about 82,244 (295)

Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants [PDF]

Addiction Science & Clinical Practice
Introduction Buprenorphine is an effective medication for opioid use disorder (OUD) treatment; however, stigma surrounding substance use may deter individuals from seeking treatment and contribute to lower engagement once treatment is initiated.
Bailey Campbell, Lindsey R. Riback, Juan Gatica Portillo, Stephanie Maricic, Aaron D. Fox   +4 more
doaj   +2 more sources

Buprenorphine initiation from fentanyl using low-dose intramuscular ketamine: a pilot study [PDF]

Addiction Science & Clinical Practice
Background Buprenorphine is an effective medication for treating opioid use disorder but is underutilized partly due to patient apprehensiveness of the severe withdrawal symptoms it can induce when started, particularly by fentanyl-dependent individuals.
J. Luke Engeriser, Thomas Hutch, Crystal L. Smith, Zach Orme, Evan Chavers, Lucinda A. Grande   +5 more
doaj   +2 more sources

Buprenorphine [PDF]

Acta Crystallographica Section E Structure Reports Online, 2014
In the crystal structure of a semi-synthetic opioid drug buprenorphine, C29H41NO4{systematic name: (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol}, the cyclopropylmethyl group is disordered over two sites with an occupancy factor of 0.611 (3) for the major component.
Jaroslaw Mazurek, Marcel Hoffmann, Anna Fernandez Casares, Phillip D. Cox, Mathew D. Minardi   +4 more
openaire   +4 more sources

Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study

Harm Reduction Journal, 2023
Background Recent policies have lessened restrictions around prescribing buprenorphine-naloxone (buprenorphine) for the treatment of opioid use disorder (OUD).
Joëlla W. Adams, Michael Duprey, Sazid Khan, Jessica Cance, Donald P. Rice, Georgiy Bobashev   +5 more
doaj   +1 more source

Postoperative respiratory depression in patients on sublingual buprenorphine: a retrospective cohort study for comparison between postoperative continuation and discontinuation of buprenorphine

JA Clinical Reports, 2022
Background We tested the hypothesis that patients who continued buprenorphine postoperatively experience postoperative respiratory depression less frequently than those who discontinued buprenorphine.
Ryu Komatsu, Michael D. Singleton, Katherin A. Peperzak, Jiang Wu, Emily M. Dinges, Laurent A. Bollag   +5 more
doaj   +1 more source

Implementation of buprenorphine services in NYC syringe services programs: a qualitative process evaluation

Harm Reduction Journal, 2022
Background Syringe services programs (SSPs) hold promise for providing buprenorphine treatment access to people with opioid use disorder (OUD) who are reluctant to seek care elsewhere.
Andrea Jakubowski, Caroline Rath, Alex Harocopos, Monique Wright, Alice Welch, Jessica Kattan, Czarina Navos Behrends, Teresa Lopez-Castro, Aaron D. Fox   +8 more
doaj   +1 more source

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France

Harm Reduction Journal, 2021
Background Some people do not benefit from oral administration of opioid agonist treatment, and an intravenous (IV) formulation may be more suitable. Our objective was to evaluate the willingness of people who regularly inject sublingual buprenorphine to
Salim Mezaache, Patrizia Carrieri, Laélia Briand-Madrid, Virginie Laporte, Alain Morel, Daniela Rojas Castro, Perrine Roux   +6 more
doaj   +1 more source

Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018

Drug and Alcohol Dependence Reports, 2023
Background: Although use of buprenorphine for treating opioid use disorder increased over the past decade, buprenorphine utilization remains limited in lower-income and rural areas.
Olivia K. Golan, Flora Sheng, Andrew W. Dick, Mark Sorbero, Daniel J. Whitaker, Barbara Andraka-Christou, Therese Pigott, Adam J. Gordon, Bradley D. Stein   +8 more
doaj   +1 more source

Buprenorphine reduces methamphetamine intake and drug seeking behavior via activating nociceptin/orphanin FQ peptide receptor in rats

Frontiers in Psychiatry, 2022
Buprenorphine, which has been approved for the treatment of opioid dependence, reduces cocaine consumption by co-activating μ-opioid receptors and nociceptin/orphanin FQ peptide (NOP) receptors. However, the role of buprenorphine in methamphetamine (METH)
Fangmin Wang, Fangmin Wang, Fangmin Wang, Wenwen Shen, Yujia Cai, Xin Zhang, Han Du, Miaojun Lai, Huifen Liu, Evelyne Kohli, Evelyne Kohli, Wenhua Zhou   +11 more
doaj   +1 more source

Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants

Addiction Science & Clinical Practice, 2022
Background Medications for opioid use disorder (MOUDs), including methadone, buprenorphine, and naltrexone, decrease mortality and morbidity for people with opioid use disorder (OUD).
Barbara Andraka-Christou, Cory Page, Victoria Schoebel, Jessica Buche, Rebecca L. Haffajee   +4 more
doaj   +1 more source